The Diffusion-weighted Imaging Perfusion Fraction F is a Potential Marker of Sorafenib Treatment in Advanced Hepatocellular Carcinoma: a Pilot Study

Overview

Journal Eur Radiol

Specialty Radiology

Date 2010 Aug 5

PMID 20683597

Citations 67

Authors

Maite Lewin

Laetitia Fartoux

Alexandre Vignaud

Lionel Arrive

Yves Menu

Olivier Rosmorduc

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the total Apparent Diffusion Coefficient (ADC), the pure Diffusion coefficient (D) and the perfusion fraction (f) in advanced hepatocellular carcinoma (HCC) under sorafenib treatment.

Materials And Methods: Two target tumors were prospectively analyzed in 12 patients at baseline, 2-weeks and 2-months treatment using b values of 0, 200, 400, 800 s/mm. Repeatability error was estimated on a healthy volunteer.

Results: Lesion sizes, ADC and D values did not significantly change during treatment (overall mean values, respectively, 47.8 ± 31.0 mm, 1.34 ± 0.14 × 10⁻³ mm² s and 1.18 ± 0.22 × 10⁻³ mm²/s). However, f values significantly increased in seven responder patients (+38.39% at 2-weeks, +50.94% at 2-months, P = 0.005) while they decreased in five non responder patients (-41.93% at 2-weeks, P = 0.006). Furthermore, f was inversely correlated with αFP levels (P = 0.032) and responder patients had a higher mean overall survival (OS) than non responder patients (12.29 ± 4.46 vs. 7.80 ± 4.9 months). The % variation of f relative to baseline at 2-months was correlated with OS (P = 0.038) and symptomatic time to progression (P = 0.022).

Conclusion: Contrary to ADC and D, the perfusion fraction f is a valuable marker of sorafenib treatment in advanced HCC.

Citing Articles

Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy.

Caliskan Yildirim E, Ergun Y World J Gastrointest Oncol. 2024; 16(12):4757-4761.

PMID: 39678807 PMC: 11577366. DOI: 10.4251/wjgo.v16.i12.4757.

Dynamic Contrast Enhanced-MRI and Apparent Diffusion Coefficient Quantitation for Differentiate Hepatocellular Carcinoma from Hepatocellular Adenoma.

Alareer H, Taher H, Abdullah A Asian Pac J Cancer Prev. 2024; 25(3):931-937.

PMID: 38546075 PMC: 11152382. DOI: 10.31557/APJCP.2024.25.3.931.

Evaluation of Local Vascular Perfusion in the Lower Extremities on Intravoxel Incoherent Motion Imaging before and after Endovascular Therapy.

Maruyama M, Yoshizako T, Aso H, Maruyama M, Araki H, Yoshida R Cardiovasc Intervent Radiol. 2024; 47(4):494-502.

PMID: 38446209 DOI: 10.1007/s00270-024-03672-6.

Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.

Zhao M, Guo Z, Zou Y, Li X, Yan Z, Chen M Hepatol Int. 2023; 18(1):4-31.

PMID: 37864725 DOI: 10.1007/s12072-023-10599-6.

A correlative study between IVIM-DWI parameters and VEGF and MMPs expression in hepatocellular carcinoma.

Yang C, Wei X, Zheng J, Tao Y, Gong X, Li L Quant Imaging Med Surg. 2023; 13(3):1887-1898.

PMID: 36915336 PMC: 10006110. DOI: 10.21037/qims-22-271.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Lewin M, Poujol-Robert A, Boelle P, Wendum D, Lasnier E, Viallon M . Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology. 2007; 46(3):658-65. DOI: 10.1002/hep.21747. View

Koh D, Blackledge M, Collins D, Padhani A, Wallace T, Wilton B . Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol. 2009; 19(11):2728-38. DOI: 10.1007/s00330-009-1469-4. View

Horger M, Lauer U, Schraml C, Berg C, Koppenhofer U, Claussen C . Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer. 2009; 9:208. PMC: 2714320. DOI: 10.1186/1471-2407-9-208. View

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

Kamel I, Liapi E, Reyes D, Zahurak M, Bluemke D, Geschwind J . Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009; 250(2):466-73. PMC: 6944072. DOI: 10.1148/radiol.2502072222. View

Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanas A, Gourtsoyiannis N . Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol. 2007; 18(3):486-92. DOI: 10.1007/s00330-007-0798-4. View

Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H . Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23(7 Pt 2):e189-97. DOI: 10.1111/j.1440-1746.2008.05340.x. View

Semela D, Dufour J . Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004; 41(5):864-80. DOI: 10.1016/j.jhep.2004.09.006. View

10.

Lewin M, Arrive L, Lacombe C, Vignaud A, Azizi L, Raynal M . [Diffusion-weighted MR imaging of liver pathology: principles and clinical applications]. J Radiol. 2010; 91(1 Pt 1):11-26. DOI: 10.1016/s0221-0363(10)70002-0. View

11.

Llovet J, Di Bisceglie A, Bruix J, Kramer B, Lencioni R, Zhu A . Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(10):698-711. DOI: 10.1093/jnci/djn134. View

12.

Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H . Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology. 1999; 210(3):617-23. DOI: 10.1148/radiology.210.3.r99fe17617. View

13.

Kamel I, Bluemke D, Ramsey D, Abusedera M, Torbenson M, Eng J . Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003; 181(3):708-10. DOI: 10.2214/ajr.181.3.1810708. View

14.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

15.

Mannelli L, Kim S, Hajdu C, Babb J, Clark T, Taouli B . Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol. 2009; 193(4):1044-52. DOI: 10.2214/AJR.08.1461. View

16.

Koh D, Collins D . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188(6):1622-35. DOI: 10.2214/AJR.06.1403. View

17.

Taouli B, Koh D . Diffusion-weighted MR imaging of the liver. Radiology. 2009; 254(1):47-66. DOI: 10.1148/radiol.09090021. View

18.

Padhani A, Liu G, Koh D, Chenevert T, Thoeny H, Takahara T . Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009; 11(2):102-25. PMC: 2631136. DOI: 10.1593/neo.81328. View

19.

Luciani A, Vignaud A, Cavet M, Tran Van Nhieu J, Mallat A, Ruel L . Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study. Radiology. 2008; 249(3):891-9. DOI: 10.1148/radiol.2493080080. View

20.

Chen C, Li C, Kuo Y, Jaw T, Wu D, Jao J . Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience. Radiology. 2006; 239(2):448-56. DOI: 10.1148/radiol.2392042202. View